We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
- Authors
Martin, H. L.; Ohara, K.; Kiberu, A.; Van Hagen, T.; Davidson, A.; Khattak, M. A.
- Abstract
Background The prognostic significance of various systemic inflammation-based markers has been explored in different cancers. These markers can be used to assist with decision-making in oncology clinics. Aim The aim of this study was to investigate the prognostic significance of three systemic inflammation-based factors: neutrophil-lymphocyte ratio ( NLR), platelet-lymphocyte ratio ( PLR) and modified Glasgow Prognostic Score (m GPS) in patients with advanced pancreatic cancer. Methods Data were collected retrospectively for advanced pancreatic cancer patients treated between 1 January 2008 and 31 December 2012 at the Royal Perth Hospital. The ratios were dichotomised as <5 versus ≥5 for NLR and <200 versus ≥200 for PLR. Modified Glasgow Prognostic Scores were scored as: m GPS '0' = both C-reactive protein ( CRP) and albumin normal, m GPS '1' = elevated CRP < 10 mg/L and m GPS '2' = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out. Results Data were evaluable for 124 patients. Median survivals based on the three inflammation-based prognostic markers evaluated were: NLR <5 versus ≥5 = 8.5 months versus 2.6 months respectively ( P = 0.0007; hazard ratio ( HR) 1.81), PLR <200 versus ≥200 = 9.1 months versus 4 months respectively ( P = 0.007; HR 1.64) and m GPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively ( P = 0.0004). Besides Eastern Cooperative Oncology Group performance status, NLR, PLR and m GPS were significant independent prognostic markers both on univariate as well as multivariate analysis. Conclusions Our findings suggest that the NLR, PLR and m GPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.
- Subjects
WESTERN Australia; PANCREATIC tumors; C-reactive protein; CONFIDENCE intervals; INFLAMMATION; MULTIVARIATE analysis; SERUM albumin; STATISTICS; TUMOR markers; PROPORTIONAL hazards models; RETROSPECTIVE studies; DATA analysis software; DESCRIPTIVE statistics; KAPLAN-Meier estimator; PROGNOSIS
- Publication
Internal Medicine Journal, 2014, Vol 44, Issue 7, p676
- ISSN
1444-0903
- Publication type
Article
- DOI
10.1111/imj.12453